Oxiracetam in dementia: a double-blind, placebo-controlled study

Area of Science:

• Neuroscience
• Pharmacology
• Geriatrics

Background:

• Dementia, including primary degenerative, multi-infarct, and mixed types, significantly impacts patient quality of life and cognitive function.
• Current treatments offer limited efficacy, necessitating research into novel therapeutic agents.

Purpose of the Study:

• To evaluate the efficacy and tolerability of oxiracetam compared to placebo in patients with dementia.
• To assess the impact of oxiracetam on cognitive performance and quality of life.

Main Methods:

• A multicentre, double-blind, placebo-controlled study involving 65 patients with dementia.
• Patients received either oxiracetam (800 mg) or placebo twice daily for 12 weeks.
• Efficacy was measured using a comprehensive neuropsychological battery and a quality of life scale.

Main Results:

• Oxiracetam demonstrated a statistically significant improvement in quality of life compared to placebo (p < 0.01).
• Significant cognitive benefits were observed in specific neuropsychological tests, including controlled associations and short story recall.
• Oxiracetam was generally well-tolerated, with a low incidence of adverse events.

Conclusions:

• Oxiracetam is an effective treatment for improving quality of life and certain cognitive functions in patients with dementia.
• The drug exhibits a favorable tolerability profile, supporting its potential as a therapeutic option for dementia.